Latest news and press releases about Niagen Bioscience Inc (NAGE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredi...
Price
| Price | $3.00 |
| Market Cap | $239M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.45 |
| Price / Book | 2.88 |
| EV / EBITDA | 9.62 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 20.50% |
| Return on Invested Capital | 8.75% |
| Return on Assets | 15.00% |
| Gross Margin | 64.24% |
| Operating Margin | 6.67% |
| Net Margin | 12.39% |
Related companies: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of NAGE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks